159 related articles for article (PubMed ID: 32511917)
1. Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.
Waaler J; Leenders RGG; Sowa ST; Alam Brinch S; Lycke M; Nieczypor P; Aertssen S; Murthy S; Galera-Prat A; Damen E; Wegert A; Nazaré M; Lehtiö L; Krauss S
J Med Chem; 2020 Jul; 63(13):6834-6846. PubMed ID: 32511917
[TBL] [Abstract][Full Text] [Related]
2. Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II.
Leenders RGG; Brinch SA; Sowa ST; Amundsen-Isaksen E; Galera-Prat A; Murthy S; Aertssen S; Smits JN; Nieczypor P; Damen E; Wegert A; Nazaré M; Lehtiö L; Waaler J; Krauss S
J Med Chem; 2021 Dec; 64(24):17936-17949. PubMed ID: 34878777
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.
Anumala UR; Waaler J; Nkizinkiko Y; Ignatev A; Lazarow K; Lindemann P; Olsen PA; Murthy S; Obaji E; Majouga AG; Leonov S; von Kries JP; Lehtiö L; Krauss S; Nazaré M
J Med Chem; 2017 Dec; 60(24):10013-10025. PubMed ID: 29155568
[TBL] [Abstract][Full Text] [Related]
4. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
[TBL] [Abstract][Full Text] [Related]
5. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
6. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
[TBL] [Abstract][Full Text] [Related]
7. Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
Jain MR; Mohapatra J; Bandhyopadhyay D; Chatterjee A; Ghoshdastidar K; Patel D; Patel A; Bhayani H; Srivastava BK; Shedage SA; Kadam P; Sundar R; Patel H; Giri P; Patel P; Gupta L; Srinivas NR; Patel PR; Desai RC
Cancer Chemother Pharmacol; 2018 Oct; 82(4):635-647. PubMed ID: 30046848
[TBL] [Abstract][Full Text] [Related]
8. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
9. Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
Shirai F; Mizutani A; Yashiroda Y; Tsumura T; Kano Y; Muramatsu Y; Chikada T; Yuki H; Niwa H; Sato S; Washizuka K; Koda Y; Mazaki Y; Jang MK; Yoshida H; Nagamori A; Okue M; Watanabe T; Kitamura K; Shitara E; Honma T; Umehara T; Shirouzu M; Fukami T; Seimiya H; Yoshida M; Koyama H
J Med Chem; 2020 Apr; 63(8):4183-4204. PubMed ID: 32202790
[TBL] [Abstract][Full Text] [Related]
10. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
Voronkov A; Holsworth DD; Waaler J; Wilson SR; Ekblad B; Perdreau-Dahl H; Dinh H; Drewes G; Hopf C; Morth JP; Krauss S
J Med Chem; 2013 Apr; 56(7):3012-23. PubMed ID: 23473363
[TBL] [Abstract][Full Text] [Related]
11.
Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
[TBL] [Abstract][Full Text] [Related]
12. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
[TBL] [Abstract][Full Text] [Related]
13. Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase.
Jang MK; Mashima T; Seimiya H
Mol Cancer Ther; 2020 Mar; 19(3):765-776. PubMed ID: 31907221
[TBL] [Abstract][Full Text] [Related]
14. Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases.
Shultz MD; Majumdar D; Chin DN; Fortin PD; Feng Y; Gould T; Kirby CA; Stams T; Waters NJ; Shao W
J Med Chem; 2013 Sep; 56(17):7049-59. PubMed ID: 23879431
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
[TBL] [Abstract][Full Text] [Related]
16. Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.
Johannes JW; Almeida L; Daly K; Ferguson AD; Grosskurth SE; Guan H; Howard T; Ioannidis S; Kazmirski S; Lamb ML; Larsen NA; Lyne PD; Mikule K; Ogoe C; Peng B; Petteruti P; Read JA; Su N; Sylvester M; Throner S; Wang W; Wang X; Wu J; Ye Q; Yu Y; Zheng X; Scott DA
Bioorg Med Chem Lett; 2015 Dec; 25(24):5743-7. PubMed ID: 26546219
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
[TBL] [Abstract][Full Text] [Related]
19. Structural basis and selectivity of tankyrase inhibition by a Wnt signaling inhibitor WIKI4.
Haikarainen T; Venkannagari H; Narwal M; Obaji E; Lee HW; Nkizinkiko Y; Lehtiö L
PLoS One; 2013; 8(6):e65404. PubMed ID: 23762361
[TBL] [Abstract][Full Text] [Related]
20. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
